Simeprevir
Back to searchMolecule Structure
Scientific Name
Simeprevir
Description of the Drug
Simeprevir is a direct-acting antiviral agent that inhibits HCV NS3/4A protease to treat chronic hepatitis C virus (HCV) infection in adults with HCV genotype 1 or 4.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06290
http://www.drugbank.ca/drugs/DB06290
Brand Name(s)
Olysio
Company Owner(s)
Janssen Products Lp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Hepatitis C virus serine protease, NS3/NS4A | PROTEIN COMPLEX | INHIBITOR | CHEMBL2095231 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL826061 | ||
| DrugBank | DB06290 | ||
| PubChem: Thomson Pharma | 50128567 | ||
| PubChem | 24873435 | ||
| Nikkaji | J3.352.107C | ||
| PDBe | 30B | ||
| BindingDB | 50336504 | ||
| DrugCentral | 4812 | ||
| Brenda | 159985 | 26671 | 159983 |
| ChemicalBook | CB82510099 | ||
| Guide to Pharmacology | 7367 | ||
| rxnorm | OLYSIO | SIMEPREVIR SODIUM | SIMEPREVIR |
| PubChem: Drugs of the Future | 87551010 | ||
| ChEBI | 134743 | ||
| ZINC | ZINC000085540268 |
